Aster DM Healthcare Ltd
Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare. [1]
- Market Cap ₹ 28,422 Cr.
- Current Price ₹ 569
- High / Low ₹ 610 / 311
- Stock P/E 4.81
- Book Value ₹ 66.8
- Dividend Yield 0.71 %
- ROCE 140 %
- ROE 188 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 149% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 72.0%
- Company has been maintaining a healthy dividend payout of 54.2%
- Company's median sales growth is 32.8% of last 10 years
Cons
- Stock is trading at 8.52 times its book value
- Promoter holding has decreased over last quarter: -1.50%
- Tax rate seems low
- Promoters have pledged 40.7% of their holding.
- Earnings include an other income of Rs.6,062 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty Smallcap 100
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 53 | 189 | 380 | 530 | 595 | 760 | 747 | 1,116 | 1,534 | 2,036 | 2,320 | |
12 | 114 | 227 | 427 | 519 | 554 | 686 | 704 | 963 | 1,240 | 1,671 | 1,864 | |
Operating Profit | -11 | -60 | -38 | -47 | 12 | 41 | 74 | 42 | 153 | 293 | 366 | 457 |
OPM % | -1,256% | -114% | -20% | -12% | 2% | 7% | 10% | 6% | 14% | 19% | 18% | 20% |
86 | 40 | 51 | 390 | 14 | 83 | 113 | 21 | 82 | 50 | 48 | 6,062 | |
Interest | 3 | 34 | 135 | 228 | 54 | 11 | 33 | 36 | 47 | 56 | 83 | 86 |
Depreciation | 1 | 22 | 48 | 68 | 59 | 64 | 89 | 95 | 99 | 104 | 121 | 145 |
Profit before tax | 72 | -77 | -170 | 47 | -87 | 49 | 65 | -68 | 90 | 182 | 209 | 6,288 |
Tax % | 2% | 1% | 0% | 0% | 0% | 1% | 6% | 1% | -0% | 5% | 25% | 1% |
70 | -78 | -170 | 47 | -87 | 48 | 61 | -69 | 90 | 173 | 157 | 6,209 | |
EPS in Rs | 1.86 | -2.00 | -4.21 | 1.16 | -1.73 | 0.95 | 1.21 | -1.38 | 1.81 | 3.47 | 3.14 | 124.30 |
Dividend Payout % | 89% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 64% | 99% |
Compounded Sales Growth | |
---|---|
10 Years: | 46% |
5 Years: | 25% |
3 Years: | 28% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | 55% |
5 Years: | 149% |
3 Years: | 303% |
TTM: | 3642% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 45% |
3 Years: | 49% |
1 Year: | 57% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 44% |
3 Years: | 72% |
Last Year: | 188% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 | 500 |
Reserves | 103 | 209 | 535 | 1,925 | 2,421 | 2,475 | 2,434 | 2,367 | 2,081 | 2,257 | 2,420 | 2,840 |
266 | 384 | 1,914 | 645 | 110 | 125 | 349 | 417 | 895 | 1,072 | 1,216 | 1,200 | |
24 | 124 | 168 | 251 | 257 | 271 | 273 | 307 | 286 | 274 | 402 | 425 | |
Total Liabilities | 768 | 1,105 | 3,021 | 3,224 | 3,293 | 3,376 | 3,552 | 3,589 | 3,762 | 4,102 | 4,538 | 4,965 |
37 | 469 | 547 | 714 | 772 | 753 | 1,016 | 1,009 | 1,013 | 1,008 | 1,333 | 1,760 | |
CWIP | 287 | 100 | 130 | 63 | 17 | 70 | 20 | 11 | 23 | 67 | 39 | 55 |
Investments | 266 | 317 | 2,037 | 2,137 | 2,086 | 2,095 | 2,150 | 2,151 | 2,166 | 2,141 | 2,176 | 1,009 |
178 | 219 | 307 | 309 | 417 | 458 | 366 | 418 | 560 | 886 | 990 | 2,140 | |
Total Assets | 768 | 1,105 | 3,021 | 3,224 | 3,293 | 3,376 | 3,552 | 3,589 | 3,762 | 4,102 | 4,538 | 4,965 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-51 | -3 | -51 | 98 | 42 | 78 | 246 | 413 | 367 | ||||
-251 | -18 | -36 | 40 | -38 | -49 | -332 | -342 | 6,023 | ||||
222 | 95 | 7 | -126 | -12 | -18 | 92 | -67 | -6,298 | ||||
Net Cash Flow | -80 | 74 | -80 | 12 | -9 | 11 | 6 | 3 | 92 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 742 | 41 | 28 | 24 | 21 | 22 | 21 | 21 | 20 | 26 | 23 | 22 |
Inventory Days | 171 | 100 | 66 | 42 | 38 | 49 | 38 | 32 | 38 | 39 | 33 | |
Days Payable | 288 | 150 | 102 | 57 | 64 | 240 | 270 | 173 | 228 | 200 | 198 | |
Cash Conversion Cycle | 742 | -75 | -22 | -13 | 6 | -4 | -170 | -210 | -122 | -163 | -139 | -143 |
Working Capital Days | 4,109 | -59 | -48 | 77 | 29 | 86 | -45 | -40 | -22 | 8 | -6 | -0 |
ROCE % | 12% | -5% | -4% | -4% | -1% | 2% | 3% | -1% | 4% | 7% | 7% | 140% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Earnings call recording for Q4 and FY ended March 31, 2025, now available on company website.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Earnings call recording for Q4 and FY ended March 31, 2025, now available online.
-
Announcement Under Regulation 30 Of SEBI (LODR) 2015
1d - Received cautionary letter for delayed disclosure of analysts meet; no financial impact; compliance steps underway.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Newspaper Publication containing QR code to view the Audited Financial Results for the quarter and year ended March 31, 2025
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Investor presentation for the quarter and year ended March 31, 2025
Annual reports
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Nov 2024TranscriptNotesPPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Dec 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Sep 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019Transcript PPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018TranscriptPPT
-
Aug 2018Transcript PPT
-
Jun 2018Transcript PPT
Business Segments Q1 FY25
1) Hospitals and Clinics (94%): The company has a network of 19 hospitals (vs 14 hospitals in FY22) and 13 clinics. These hospitals are located in the Maharastra (1), Karnataka (4), Kerala (6), Andhra (6) & Telangana (1). [1]
This business has registered a 23% YoY revenue growth and EBITDA grew by 28% in FY24, on the backdrop of an increased bed capacity of 550 beds, and cost optimization measures. Material cost has declined from 25% in FY22 to 22% in FY24. [2] [3]